Glidden Paul F, Goldberg David B, Heldebrant Charles M
Alpha Therapeutic Corporation, 1213 John Reed Court, City of Industry, CA 91745, USA.
J Pharm Biomed Anal. 2002 Apr 15;28(2):295-302. doi: 10.1016/s0731-7085(01)00634-3.
Peripheral vascular disease is a common ailment of the aged and diabetic communities. As the numbers of these individuals increase, the need for therapeutic interventions will continue to grow. One of the possible therapies is the use of prostaglandins (PGE(1), prostacyclin and Iloprost) to decrease the vascular tone and increase vascular blood flow. Due to the hydrophobicity of the prostaglandins and prostaglandin analogues, various vehicles have been utilized to maintain the active pharmaceutical ingredient in a stable solution, e.g. alpha-cyclodextrin (Alprostadil, Edex) or emulsified lipid vehicles. In our laboratory, we designed a method for separating and assaying lipid-encapsulated PGE(1). Utilizing organic extraction, automated solid-phase extraction and precipitation techniques, we validated the measurement of the PGE(1) and PGA(1) content of the clinical drug formulation in the microgram per milliliter concentration range with an high performance liquid chromatography (HPLC) assay.
外周血管疾病是老年人和糖尿病患者群体中的常见疾病。随着这类人群数量的增加，对治疗干预措施的需求也将持续增长。一种可能的治疗方法是使用前列腺素（PGE(1)、前列环素和伊洛前列素）来降低血管张力并增加血管血流量。由于前列腺素和前列腺素类似物具有疏水性，人们使用了各种载体来将活性药物成分维持在稳定的溶液中，例如α-环糊精（前列地尔，爱力达）或乳化脂质载体。在我们实验室，我们设计了一种分离和测定脂质包裹的PGE(1)的方法。利用有机萃取、自动固相萃取和沉淀技术，我们通过高效液相色谱（HPLC）测定法验证了临床药物制剂中PGE(1)和PGA(1)含量在微克每毫升浓度范围内的测量。
